Skip to main content

3 Result(s)

within D. Ribom Remove this filter

and

  1. Article

    Open Access

    PROX1 is a predictor of survival for gliomas WHO grade II

    The clinical course of World Health Organisation grade II gliomas remains variable and their time point of transformation into a more malignant phenotype is unpredictable. Identification of biological markers ...

    T Elsir, M Qu, S G Berntsson, A Orrego, T Olofsson… in British Journal of Cancer (2011)

    Download PDF (1147 KB) View Article

  2. No Access

    Article

    Adding 11C-methionine PET to the EORTC prognostic factors in grade 2 gliomas

    The management of adult patients with grade 2 gliomas remains a challenge for the clinical neuro-oncologist. Several clinical prognostic factors appear to be as important as treatment factors in determining ou...

    A. Smits, E. Westerberg, D. Ribom in European Journal of Nuclear Medicine and M… (2008)

  3. No Access

    Article

    Growth factor analysis of low-grade glioma CSF: PDGF and VEGF are not detectable

    Platelet-derived growth factor (PDGF), vascular endothelial growth factor (VEGF) and fibroblast growth factor 2 (FGF-2) are involved in the development of grade 2 gliomas. The aim of the present study was to ...

    D. Ribom, A. Larsson, K. Pietras, A. Smits in Neurological Sciences (2003)